Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United States

被引：2

作者：

Castillo, Jorge J. ^{[1
]}

Kingsley, Edwin C. ^{[2
]}

Narang, Mohit ^{[3
]}

Yimer, Habte A. ^{[4
]}

Dasanu, Constantin A. ^{[5
]}

Melear, Jason M. ^{[6
]}

Coleman, Morton ^{[7
]}

Farber, Charles M. ^{[8
]}

Shulman, Jonah ^{[9
]}

Mantovani, Emily H. ^{[10
,11
]}

Zhang, Xiaowei ^{[10
,11
]}

Cohen, Aileen ^{[10
,11
]}

Huang, Jane ^{[10
,11
]}

机构：

[1] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA

[2] Comprehens CancerCtr Nevada, Las Vegas, NV USA

[3] US Oncol Res, Maryland Hematol Oncol, Columbia, MD USA

[4] US Oncol Res, Texas Oncol, Tyler, TX USA

[5] Eisenhower Hlth, Lucy Curci Canc Ctr, Rancho Mirage, CA USA

[6] Austin Midtown, US Oncol Res, Texas Oncol, Austin, TX USA

[7] Weill Cornell Med, Clin Res Alliance, New York, NY USA

[8] Morristown Med Ctr, Atlantic Hematol Oncol, Morristown, NJ USA

[9] Icahn Sch Med Mt Sinai, New York, NY USA

[10] BeiGene Beijing Co Ltd Beijing, San Mateo, CA USA

[11] BeiGene Inc, San Mateo, CA USA

来源：

EJHAEM | 2023年 / 4卷 / 01期

关键词：

BTK inhibitor; Waldenstr & ouml; m macroglobulinemia; zanubrutinib; WALDENSTROM MACROGLOBULINEMIA;

D O I：

10.1002/jha2.619

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：301 / 304

页数：4

共 7 条

[1] Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with Waldenström macroglobulinemia and CLL/SLL
Izutsu, Koji
Ishikawa, Takayuki
Shimada, Kazuyuki
Kubo, Kohmei
Kondo, Takeshi
Fujimoto, Katsuya
Fujisaki, Tomoaki
Kurahashi, Shingo
Nagafuji, Koji
Sakai, Rika
Jo, Tatsuro
Nakazato, Tomonori
Sunami, Kazutaka
Kasahara, Senji
Cohen, Aileen
Takai, Motohisa
Zhong, Jinhua
Takeuchi, Masahiro
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025, 121 (04) : 483 - 493
[2] Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia
Castillo, Jorge J.
Branagan, Andrew R.
Sermer, David
Flynn, Catherine A.
Meid, Kirsten
Little, Megan
Stockman, Katherine
White, Timothy
Canning, Alexa
Guerrera, Maria L.
Ko, Amanda
Liu, Shirong
Liu, Xia
Richardson, Kris
Tsakmaklis, Nicholas
Patterson, Christopher J.
Hunter, Zachary R.
Treon, Steven P.
Sarosiek, Shayna
BLOOD, 2024, 143 (07) : 582 - 591
[3] Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia
Chohan, Karan L.
Kapoor, Prashant
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2024, 19 (04) : 163 - 174
[4] Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
Tam, Constantine S.
Opat, Stephen
D'Sa, Shirley
Jurczak, Wojciech
Lee, Hui-Peng
Cull, Gavin
Owen, Roger G.
Marlton, Paula
Wahlin, Bjoern E.
Garcia-Sanz, Ramon
McCarthy, Helen
Mulligan, Stephen
Tedeschi, Alessandra
Castillo, Jorge J.
Czyz, Jaros law
De Larrea, Carlos Fernandez
Belada, David
Libby, Edward
Matous, Jeffrey
Motta, Marina
Siddiqi, Tanya
Tani, Monica
Trneny, Marek
Minnema, Monique C.
Buske, Christian
Leblond, Veronique
Treon, Steven P.
Trotman, Judith
Wu, Binghao
Yu, Yiling
Shen, Zhirong
Chan, Wai Y.
Schneider, Jingjing
Allewelt, Heather
Cohen, Aileen
Dimopoulos, Meletios A.
BLOOD ADVANCES, 2024, 8 (07) : 1639 - 1650
[5] A Phase II Study to Evaluate the Efficacy of Bortezomib in Combination with Thalidomide in Treatment-Naïve Waldenstrom Macroglobulinemia Patients
Byun, Ja Min
Shin, Junghoon
Kim, Sang -A
Park, Hyunkyung
Lee, Jiyun
Shin, Dong-Yeop
Hong, Junshik
Lee, Jeong-Ok
Bang, Soo-Mee
Kim, Inho
Yoon, Sung-Soon
Koh, Youngil
CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 675 - 680
[6] Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia
Tomowiak, Cecile
Poulain, Stephanie
Nudel, Morgane
Feugier, Pierre
Herbaux, Charles
Mahe, Beatrice
Morel, Pierre
Aurran, Therese
Tournilhac, Olivier
Lepretre, Stephane
Assaad, Souad
Villemagne, Bruno
Casasnovas, Olivier
Lhermitte, Adeline
Roos-Weil, Damien
Torregrosa-Diaz, Jose
Chevret, Sylvie
Leblond, Veronique
ANNALS OF HEMATOLOGY, 2025, 104 (01) : 685 - 690
[7] Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis
Kim, Jowon Laura
Gerrie, Alina S.
Savage, Kerry Joane
Villa, Diego
Scott, David
Craig, Jeffrey W.
Farinha, Pedro
Skinnider, Brian
Slack, Graham
Connors, Joseph M.
Sehn, Laurie H.
Venner, Christopher
Freeman, Ciara L.
LEUKEMIA & LYMPHOMA, 2024, 65 (03) : 346 - 352

← 1 →